Issued on behalf of Avant Technologies Inc.

Trading as OTCQB: AVAI and soon to be renamed Avai Bio, Avant Technologies is advancing next-generation therapies with Austrianova to harness the “longevity protein” Klotho addressing Alzheimer’s, heart disease, and other age-related conditions.

In 2014, something extraordinary happened in a clinical trial that wasn’t supposed to happen at all.

Researchers testing an Alzheimer’s vaccine gave their control group what they thought was an inactive placebo.

Instead, patients receiving this “inactive” compound showed measurably better cognitive function and preserved brain tissue.

That accidental discovery has now evolved into what could be one of the most significant opportunities in longevity medicine and Avant Technologies (OTCQB: AVAI) offers public investors rare access to this breakthrough.

The Longevity Gold Rush

The longevity field has shifted from fringe science to a capital-intensive race.

According to a Wall Street Journal analysis of investment deals over the past 25 years, the ultrawealthy have poured more than $5 billion into longevity ventures.[1]

Bryan Johnson, the tech millionaire spending $2 million annually on anti-aging protocols, has become the public face of extreme longevity efforts, though his recent facial fat injection experiment resulted in severe allergic reactions[2].

Jeff Bezos has reportedly backed Altos Labs, pouring billions into cell rejuvenation research[3]. Peter Thiel has invested millions in anti-aging companies including Methuselah Foundation and Unity Biotechnology, with his quest for longer life spanning nearly a dozen companies that raised more than $700 million[4]. Sam Altman, CEO of OpenAI, is funding Retro Biosciences with a $180M war chest[5].

Major corporations are joining the race.

Johnson & Johnson has invested in longevity research through its Innovation unit[6].

Alphabet founded Calico to decode aging biology[7], and AbbVie has partnered with Calico in a $1.5 billion collaboration[8].

Moderna CEO Stéphane Bancel tried a diet designed to mimic fasting effects and subsequently led a $47 million funding round for the scientist’s longevity company[9].

The scale of investment is staggering. Altos Labs raised $3 billion (the largest of any longevity company)[10], while BioAge Labs raised $559 million[11] and Insilico Medicine raised over $500 million[12]. The average funding round for longevity companies has grown by more than 20% in the past decade to nearly $43 million in 2025[13].

Meanwhile, in 2025, the $101M XPRIZE Healthspan competition announced its semifinalists, marking a global race to extend healthy human years[14].

For everyday investors, access to this trend is almost impossible. Most deals are private.

That’s where Avant Technologies (OTCQB: AVAI) comes in.

The Klothonova Opportunity

Avant Technologies has formed Klothonova, a 50/50 joint venture with Austrianova, to develop therapies based on the Klotho protein, which was the same pathway behind that accidental 2014 discovery we talked about above.

According to the signed joint venture and licensing agreement, Avant Technologies will hold equal ownership with Austrianova and provide capital to advance Klotho-based therapeutic programs.

Why Klotho Matters

Klotho is sometimes called the “longevity protein.” Here’s why:

Lifespan Impact: In studies, higher Klotho levels correlate with up to 30% increased lifespan[15]
Human Data: Individuals with lowest Klotho levels had 31% higher mortality rates than those with higher levels[16]
Age Decline: Natural Klotho levels drop by 50% after age 40[17]
Multiple Benefits: Affects brain, heart, kidneys, and immune function simultaneously[18]

The Technology Platform

Austrianova brings world-class expertise to the joint venture:

30+ years of cell encapsulation expertise
Cell-in-a-Box® technology already approved and used clinically
Over 50 peer-reviewed publications backing their technology
Established GMP-grade cell products and manufacturing capabilities
Proven partnerships with global pharmaceutical and biotech companies
Proprietary cell-encapsulation technology for Klotho overexpression

Avant Technologies contributes:

Capital investment and additional resources
Strategic vision for commercializing transformative healthcare solutions
Public market access for retail investors

Comprehensive Treatment Strategy

Klothonova’s Approach – Encapsulated Cell Therapy

Long-term Klotho delivery via implantable capsules using Austrianova’s proven cell-encapsulation technology
Sustained therapeutic effects through overexpression of the Klotho protein
Targeting multiple conditions: Alzheimer’s disease, heart disease, cancer, kidney disease, and other age-related conditions
Focus on longevity promotion across global markets

Investment Highlights

✓ Public Access: One of the only listed companies giving exposure to longevity biotech usually reserved for private capital

✓ Proven Science: Based on accidental clinical discovery, not speculative research

✓ World-Class Partnership: Austrianova brings 30+ years of cell encapsulation expertise, 50+ peer-reviewed publications, and established GMP manufacturing

✓ Equal Partnership: First product targeted within 6-12 months, profitability projected within 18 months

✓ Established Technology: Leverages Austrianova’s proven Cell-in-a-Box® technology already approved and used clinically

✓ Massive Markets: Alzheimer’s, cardiovascular disease, cancer, kidney disease, and broader aging therapy markets

The Systemic Advantage

What makes this opportunity unique is how it addresses the fundamental problem with current medical approaches. Traditional medicine treats the symptoms of aging as separate conditions—high blood pressure, cognitive decline, kidney dysfunction—each requiring different drugs with different side effects.

The Klotho approach is different. By addressing underlying aging mechanisms, a single therapeutic pathway can potentially impact multiple systems simultaneously:

Alzheimer’s & Cognitive Decline: $32.8 billion global market by 2033[19]
Cardiovascular Disease: World’s leading cause of death[20]
Kidney Disease: Affects 850 million people worldwide[21]
Metabolic Disorders: Growing epidemic tied to aging
Immune Dysfunction: Root cause of many age-related diseases

This convergence of proven science (decades of Klotho research since its 1997 discovery), established technology (Austrianova’s three decades of cell encapsulation), and strategic timing (longevity field transitioning from research to commercialization) creates what may be a once-in-a-generation investment opportunity.

Learn More

Scientific Background:

Over 3,600 published research papers on Klotho protein
Clinical trial data available through peer-reviewed publications
XPRIZE Healthspan competition recognition

Company Information:

Joint Venture and License Agreement formation between Avant Technologies and Austrianova
Austrianova’s 30+ year cell encapsulation technology development and GMP manufacturing capabilities
Avant Technologies (OTCQB: AVAI) investor relations

Industry Context:

Longevity medicine research developments
Cell encapsulation technology applications
mRNA therapeutic platform advances

*Discover why Avant Technologies (**OTCQB: AVAI) is positioning itself at the forefront of the longevity revolution. Read the full scientific background, or sign up below for updates on this developing opportunity.*

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

SOURCES CITED

[1] https://www.wsj.com/health/wellness/billionaires-longevity-health-04dd205c?gaa_at=eafs&gaa_n=ASWzDAiM0RGKGr_X9XB-BGy3taM2xjutTSw3l0yvmQZjD8ZmFFh2_1G0bOK6NfVd44Y%3D&gaa_ts=68c05fd1&gaa_sig=a8G5n4h_FuYaXokG3Dgoib0SwTkcHaNfGmTfbrOJS0o8LQOceI_lrYF65JA9waZeRQQDj8kNgm9k8fhoJFTIUg%3D%3D

[2] https://fortune.com/well/article/bryan-johnson-live-longer-unrecognizable-anti-aging-procedure/

[3] https://interestingengineering.com/health/jeff-bezos-backed-lab-hired-nobel-laureate-top-scientists-to-beat-death

[4] https://www.lovemoney.com/gallerylist/81914/from-elon-musk-to-jeff-bezos-the-superrich-using-tech-to-live-forever

[5] https://fortune.com/2025/01/24/sam-altman-ai-biotech-1-billion-funding-extend-human-lifespan/

[6] https://healthylongevitychallenge.org/johnson-johnson-innovation-names-awardees-in-the-nam-healthy-longevity-2022-quickfire-challenge/#:~:text=September%2027%2C%202022%20%E2%80%94%20Johnson%20&,flowbone

[7] https://www.fiercebiotech.com/biotech/alphabets-calico-stitches-571m-deal-mabwells-anti-aging-asset

[8] https://www.calicolabs.com/press/abbvie-and-calico-announce-second-extension-of-collaboration-focused-on-aging-and-age-related-diseases/

[9] https://www.prnewswire.com/news-releases/l-nutra-closes-47-million-in-first-stage-of-growth-investment-round-301979661.html

[10] https://www.fiercebiotech.com/biotech/altos-bursts-out-stealth-3b-a-dream-team-c-suite-and-a-wildly-ambitious-plan-to-reverse#:~:text=Altos%20bursts%20out%20of%20stealth,presents%20to%20improve%20human%20health.

[11] https://www.fiercebiotech.com/biotech/novartis-and-bioage-take-age-related-diseases-new-550m-pact#:~:text=BioAge%20secures%20Novartis%20deal%20worth,the%20table%20for%20each%20company.